LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Article ; Online: Socio-economic disparities in the dispensation of antibiotics in Sweden 2016-2017: An intersectional analysis of individual heterogeneity and discriminatory accuracy.

    Wemrell, Maria / Lenander, Cecilia / Hansson, Kristofer / Perez, Raquel Vicente / Hedin, Katarina / Merlo, Juan

    Scandinavian journal of public health

    2021  Volume 50, Issue 3, Page(s) 347–354

    Abstract: Aims: ...

    Abstract Aims:
    MeSH term(s) Anti-Bacterial Agents/therapeutic use ; Female ; Humans ; Income ; Public Health ; Socioeconomic Factors ; Sweden/epidemiology
    Chemical Substances Anti-Bacterial Agents
    Language English
    Publishing date 2021-01-18
    Publishing country Sweden
    Document type Journal Article
    ZDB-ID 1475054-5
    ISSN 1651-1905 ; 1403-4948
    ISSN (online) 1651-1905
    ISSN 1403-4948
    DOI 10.1177/1403494820981496
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 884: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Splanchnic Vein Thrombosis in Inflammatory Bowel Disease

    Maria Puig / Helena Masnou / Francisco Mesonero / Luís Menchén / Luís Bujanda / Jesús Castro / Irene González-Partida / Raquel Vicente / Carlos González-Muñoza / Marisa Iborra / Mónica Sierra / José María Huguet / María José García / Ruth De Francisco / Francisco Javier García-Alonso / Míriam Mañosa / Eugeni Domènech / on behalf of ENEIDA-GETECCU Registry

    Journal of Clinical Medicine, Vol 12, Iss 23, p

    An Observational Study from the ENEIDA Registry and Systematic Review

    2023  Volume 7366

    Abstract: Background: Thromboembolic events are frequent among patients with inflammatory bowel disease (IBD). However, there is little information on the prevalence, features and outcomes of splanchnic vein thrombosis (SVT) in patients with IBD. Aims: To describe ...

    Abstract Background: Thromboembolic events are frequent among patients with inflammatory bowel disease (IBD). However, there is little information on the prevalence, features and outcomes of splanchnic vein thrombosis (SVT) in patients with IBD. Aims: To describe the clinical features and outcomes of SVT in patients with IBD and to perform a systematic review of these data with published cases and series. Methods: A retrospective observational study from the Spanish nationwide ENEIDA registry was performed. A systematic search of the literature was performed to identify studies with at least one case of SVT in IBD patients. Results: A new cohort of 49 episodes of SVT from the Eneida registry and 318 IBD patients with IBD identified from the literature review (sixty studies: two multicentre, six single-centre and fifty-two case reports or case series) were analysed. There was a mild predominance of Crohn’s disease and the most frequent clinical presentation was abdominal pain with or without fever followed by the incidental finding in cross-sectional imaging techniques. The most frequent SVT location was the main portal trunk in two-thirds of the cases, followed by the superior mesenteric vein. Anticoagulation therapy was prescribed in almost 90% of the cases, with a high rate of radiologic resolution of SVT. Thrombophilic conditions other than IBD itself were found in at least one-fifth of patients. Conclusions: SVT seems to be a rare (or underdiagnosed) complication in IBD patients. SVT is mostly associated with disease activity and evolves suitably when anticoagulation therapy is started.
    Keywords prevalence ; splanchnic vein thrombosis ; inflammatory bowel disease ; outcome ; Medicine ; R
    Subject code 610
    Language English
    Publishing date 2023-11-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article: IMPACT OF MESALAZINE ON THE RESPONSE TO COVID-19 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. RESULTS OF A PROSPECTIVE MULTICENTRE STUDY OF GETECCU (VACOVEII STUDY).

    Deza, Diego Casas / Julián Gomara, Ana Belén / Biota, Eva Caudevilla / Beltrán, Belén / Domènech, Eugeni / Casbas, Ana Gutiérrez / Mañosa, Miriam / Zabana, Yamile / Alfaro, Lourdes Roc / Romero, Emilio Valverde / González, Elena García / Sicilia, Beatriz / Laredo, Viviana / Alcalá Escriche, María José / Velázquez, Lucia Madero / Iglesias, Rocío Ferreiro / Pérez, Antonia Palmero / Calafat, Margalida / Iturria, Saioa Rubio /
    Yudego, Irene Moraleja / Nieto, Yolanda Ber / Mateo, Sandra García / Gisbert, Javier P / Lidón, Raquel Vicente / Arias, Lara / Alfambra, Erika / Roche, Pilar Corsino / de Acosta, Manuel Barreiro / López, Santiago García

    Gastroenterologia y hepatologia

    2024  

    Abstract: Objective: the recommendations of the Spanish Ministry of Health on vaccination in risk groups include mesalazine among the treatments with a possible negative effect on its effectiveness. However, this is not the recommendation of most experts. Our ... ...

    Title translation IMPACTO DE LA MESALAZINA EN LA RESPUESTA A LA VACUNACIÓN CONTRA EL COVID-19 EN PACIENTES CON ENFERMEDAD INFLAMATORIA INTESTINAL. RESULTADOS DE UN ESTUDIO PROSPECTIVO MULTICÉNTRICO DE GETECCU (VACOVEII).
    Abstract Objective: the recommendations of the Spanish Ministry of Health on vaccination in risk groups include mesalazine among the treatments with a possible negative effect on its effectiveness. However, this is not the recommendation of most experts. Our objective was to evaluate the effect of mesalazine on the humoral response to the SARS-CoV-2 vaccine in patients with inflammatory bowel disease (IBD).
    Methods: VACOVEII is a Spanish, prospective, multicenter study promoted by GETECCU, which evaluates the effectiveness of the SARS-CoV-2 vaccine in patients with IBD. This study includes IBD patients who have recieved the full vaccination schedule and without previous COVID-19 infection. Seroconversion was set at 260 BAU/mL (centralized determination) and was assessed 6 months after full vaccination. In this subanalysis of the study, we compare the effectivenes of the vaccine between patients treated with mesalazine and patients without treatment.
    Results: A total of 124 patients without immunosuppressive therapy were included, of which 32 did not receive any treatment and 92 received only mesalazine. Six months after full vaccination, no significant differences are observed in the mean concentrations of IgG anti-S between both groups. In the multivariate analysis, antibody titers were independently associated with the use of mRNA vaccines and with SARS-CoV-2 infection.
    Conclusion: Mesalazine does not have a negative effect on the response to SARS-CoV-2 vaccines in IBD patients.
    Language Spanish
    Publishing date 2024-01-12
    Publishing country Spain
    Document type Journal Article
    ZDB-ID 632502-6
    ISSN 0210-5705
    ISSN 0210-5705
    DOI 10.1016/j.gastrohep.2023.12.012
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2044: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Effectiveness and safety of ustekinumab in bio-naïve Crohn's disease patients: a multicentre observational retrospective study.

    Teresa, Valdés Delgado / Rául, Olmedo Martín / Marisa, Iborra / Claudia, Herrera de Guisé / Esteban, Fuentes-Valenzuela / Luigi, Melcarne / Mª Mar, Martín-Rodríguez / Lilyan, Kolle Casso / Luisa, De Castro Parga / Ángel, Ponferrada Díaz / Raquel, Vicente Lidón / Noemí, Manceñido Marcos / Benito, Velayos Jiménez / Marta, Lázaro Sáez / Beatriz, López Cauce / Francisco, Mesonero Gismero / Pau, Gilabert Álvarez / Federico, Argüelles-Arias

    Therapeutic advances in gastroenterology

    2023  Volume 16, Page(s) 17562848231153560

    Abstract: Background: Clinical trials have demonstrated the efficacy and safety of ustekinumab in Crohn's disease (CD). However, more data are necessary on the effectiveness of ustekinumab in bio-naïve patients in real-life studies.: Objectives: The aim of our ...

    Abstract Background: Clinical trials have demonstrated the efficacy and safety of ustekinumab in Crohn's disease (CD). However, more data are necessary on the effectiveness of ustekinumab in bio-naïve patients in real-life studies.
    Objectives: The aim of our study was to evaluate the effectiveness and safety of ustekinumab in patients with CD refractory or intolerant to conventional therapy and without previous exposure to biological drugs.
    Design: We performed a nationwide, observational, retrospective, multicentre study including patients with CD, in which ustekinumab was used as the first biological drug.
    Methods: The corticosteroid-free clinical and biological response and remission were analysed at weeks 16, 24, 52 and 72. Clinical remission was defined as Harvey-Bradshaw index ⩽ 4 and biological remission as a faecal calprotectin (FC) <250 mg/g and C-reactive protein (CRP) <5 mg/L. Moreover, the persistence of the treatment and any adverse events were assessed.
    Results: In all, 84 patients were included in the study, males and females were equally distributed, with a median age of 63 years [interquartile range (IQR): 51-75] and a median disease duration of 6.8 years [IQR: 3.6-17.0]. The majority (86.9%) of patients were treated with ustekinumab as monotherapy, without concomitant immunosuppressive medication. The proportion of patients in corticosteroid-free clinical remission or response at weeks 16, 24, 52 and 72 was 93.3% (56/60), 86.8% (46/53), 82.2% (37/45) and 71.4% (30/42), respectively. CRP returned to normal values in 47.6%, 43.2%, 50% and 52.4% of patients at weeks 16, 24, 52 and 72, respectively. Similarly, FC was normalized in 45.5%, 45.5%, 48.6% and 50% of patients at weeks 16, 24, 52 and 72, respectively. The cumulative probability of remaining on ustekinumab treatment was 84.8% (95% confidence interval: 73.3-91.6) after 72 weeks. Ustekinumab was discontinued in 10 patients (11.9%) within 72 weeks of follow-up. Reasons for discontinuing treatment were lack of response (
    Conclusions: Ustekinumab was effective and safe in Spanish bio-naïve CD patients, showing a quicker and more durable response than obtained in patients with previous biological treatment. In this cohort of bio-naïve patients starting on ustekinumab, the average age was high.
    Plain language summary: Effectiveness and safety of ustekinumab in Crohn's disease patients not previously exposed to other biological therapies
    Language English
    Publishing date 2023-02-09
    Publishing country England
    Document type Journal Article
    ZDB-ID 2440710-0
    ISSN 1756-2848 ; 1756-283X
    ISSN (online) 1756-2848
    ISSN 1756-283X
    DOI 10.1177/17562848231153560
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Enfermedad de Crohn y colitis ulcerosa

    Beatriz Sicilia / Raquel Vicente / Fernando Gomollón

    Acta Gastroenterológica Latinoamericana, Vol 39, Iss 2, Pp 135-

    discusión de la epidemiología clásica

    2009  Volume 145

    Abstract: La incidencia y consecuentemente la prevalencia de las enfermedades Inflamatorias intestinales (EII) ha aumentado en las últimas décadas. Pueden debutar a cualquier edad sin predominio claro de sexo y con porcentajes similares a los de la población ... ...

    Abstract La incidencia y consecuentemente la prevalencia de las enfermedades Inflamatorias intestinales (EII) ha aumentado en las últimas décadas. Pueden debutar a cualquier edad sin predominio claro de sexo y con porcentajes similares a los de la población general en términos de mortalidad en su evolución natural, pero con una mayor incidencia de cáncer colorrectal relacionado claramente con la inflamación crónica y la duración de la enfermedad. Muy probablemente las EII sean enfermedades poligénicas que comparten genes que aumentarían la susceptibilidad de padecerlas y por el contrario se asocian a genes específicos para cada una de ellas (EC y CU). Entre los factores de riesgo ambientales que alterarían la respuesta inmune originando los diferentes fenotipos que conocemos de ambas enfermedades es el tabaco el que mayor significación tiene, con un comportamiento diferente en ambas enfermedades, aunque también se han descrito asociaciones con la apendicectomía, los anticonceptivos, las infecciones, la dieta, la higiene en la infancia y la toma de antiinflamatorios no esteroideos.
    Keywords Diseases of the digestive system. Gastroenterology ; RC799-869 ; Specialties of internal medicine ; RC581-951 ; Internal medicine ; RC31-1245 ; Medicine ; R
    Language Spanish
    Publishing date 2009-01-01T00:00:00Z
    Publisher Sociedad Argentina de Gastroenterología
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  6. Article ; Online: Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain

    María Chaparro / Ana Garre / Andrea Núñez Ortiz / María Teresa Diz-Lois Palomares / Cristina Rodríguez / Sabino Riestra / Milagros Vela / José Manuel Benítez / Estela Fernández Salgado / Eugenia Sánchez Rodríguez / Vicent Hernández / Rocío Ferreiro-Iglesias / Ángel Ponferrada Díaz / Jesús Barrio / José María Huguet / Beatriz Sicilia / María Dolores Martín-Arranz / Xavier Calvet / Daniel Ginard /
    Inmaculada Alonso-Abreu / Luis Fernández-Salazar / Pilar Varela Trastoy / Montserrat Rivero / Isabel Vera-Mendoza / Pablo Vega / Pablo Navarro / Mónica Sierra / José Luis Cabriada / Mariam Aguas / Raquel Vicente / Mercè Navarro-Llavat / Ana Echarri / Fernando Gomollón / Elena Guerra del Río / Concepción Piñero / María José Casanova / Katerina Spicakova / Jone Ortiz de Zarate / Emilio Torrella Cortés / Ana Gutiérrez / Horacio Alonso-Galán / Álvaro Hernández-Martínez / José Miguel Marrero / Rufo Lorente Poyatos / Margalida Calafat / Lidia Martí Romero / Pilar Robledo / Orencio Bosch / Nuria Jiménez / María Esteve Comas / José María Duque / Ana María Fuentes Coronel / Manuela Josefa Sampedro / Eva Sesé Abizanda / Belén Herreros Martínez / Liliana Pozzati / Hipólito Fernández Rosáenz / Belén Crespo Suarez / Pilar López Serrano / Alfredo J. Lucendo / Margarita Muñoz Vicente / Fernando Bermejo / José Joaquín Ramírez Palanca / Margarita Menacho / Amalia Carmona / Raquel Camargo / Sandra Torra Alsina / Nuria Maroto / Juan Nerín de la Puerta / Elena Castro / Ignacio Marín-Jiménez / Belén Botella / Amparo Sapiña / Noelia Cruz / José Luis F. Forcelledo / Abdel Bouhmidi / Carlos Castaño-Milla / Verónica Opio / Isabel Nicolás / Marcos Kutz / Alfredo Abraldes Bechiarelli / Jordi Gordillo / Yolanda Ber / Yolanda Torres Domínguez / María Teresa Novella Durán / Silvia Rodríguez Mondéjar / Francisco J. Martínez-Cerezo / Lilyan Kolle / Miriam Sabat / Cesar Ledezma / Eduardo Iyo / Óscar Roncero / Rebeca Irisarri / Laia Lluis / Isabel Blázquez Gómez / Eva María Zapata / María José Alcalá / Cristina Martínez Pascual / María Montealegre / Laura Mata / Ana Monrobel / Alejandro Hernández Camba / Luis Hernández / María Tejada / Alberto Mir / María Luisa Galve / Marta Soler / Daniel Hervías / José Antonio Gómez-Valero / Manuel Barreiro-de Acosta / Fernando Rodríguez-Artalejo / Esther García-Esquinas / Javier P. Gisbert / on behalf of the EpidemIBD study group of GETECCU

    Journal of Clinical Medicine, Vol 10, Iss 2885, p

    Large-Scale Epidemiological Study

    2021  Volume 2885

    Abstract: 1) Aims: To assess the incidence of inflammatory bowel disease (IBD) in Spain, to describe the main epidemiological and clinical characteristics at diagnosis and the evolution of the disease, and to explore the use of drug treatments. (2) Methods: ... ...

    Abstract (1) Aims: To assess the incidence of inflammatory bowel disease (IBD) in Spain, to describe the main epidemiological and clinical characteristics at diagnosis and the evolution of the disease, and to explore the use of drug treatments. (2) Methods: Prospective, population-based nationwide registry. Adult patients diagnosed with IBD—Crohn’s disease (CD), ulcerative colitis (UC) or IBD unclassified (IBD-U)—during 2017 in Spain were included and were followed-up for 1 year. (3) Results: We identified 3611 incident cases of IBD diagnosed during 2017 in 108 hospitals covering over 22 million inhabitants. The overall incidence (cases/100,000 person-years) was 16 for IBD, 7.5 for CD, 8 for UC, and 0.5 for IBD-U; 53% of patients were male and median age was 43 years (interquartile range = 31–56 years). During a median 12-month follow-up, 34% of patients were treated with systemic steroids, 25% with immunomodulators, 15% with biologics and 5.6% underwent surgery. The percentage of patients under these treatments was significantly higher in CD than UC and IBD-U. Use of systemic steroids and biologics was significantly higher in hospitals with high resources. In total, 28% of patients were hospitalized (35% CD and 22% UC patients, p < 0.01). (4) Conclusion: The incidence of IBD in Spain is rather high and similar to that reported in Northern Europe. IBD patients require substantial therapeutic resources, which are greater in CD and in hospitals with high resources, and much higher than previously reported. One third of patients are hospitalized in the first year after diagnosis and a relevant proportion undergo surgery.
    Keywords epidemiology ; incidence ; inflammatory bowel disease ; Crohn’s disease ; ulcerative colitis ; Medicine ; R
    Subject code 610
    Language English
    Publishing date 2021-06-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top